US3764679A - Iodinin as an anti-hypertensive agent - Google Patents

Iodinin as an anti-hypertensive agent Download PDF

Info

Publication number
US3764679A
US3764679A US00236179A US3764679DA US3764679A US 3764679 A US3764679 A US 3764679A US 00236179 A US00236179 A US 00236179A US 3764679D A US3764679D A US 3764679DA US 3764679 A US3764679 A US 3764679A
Authority
US
United States
Prior art keywords
iodinin
hypertensive
hypertensive agent
patients
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00236179A
Inventor
P Jones
P Somani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of US3764679A publication Critical patent/US3764679A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Definitions

  • This invention relates to a method of reducing blood pressure in hypertensive patients using iodinin as the anti-hypertensive agent.
  • lodinin is represented by the formula
  • the compound can be prepared according to the method described by U.S. Pat. No. 3,432,505.
  • lodinin has previously been reported to be an antibacterial agent (see U.S. Pat. No. 3,432,505). We have unexpectedly found that iodinin is an effective antihypertensive agent.
  • lodinin is effective as an anti-hypertensive agent at dosages of from approximately 0.1 to approximately 300 mg./kg. of body weight daily and is administered to hypertensive patients at such dosages, preferably by the oral route in divided dosages i.e., 3 to 4 times daily. It may also be co-administered with, for example, diuretics or tranquilizers.
  • the oral LD of iodinin is greater than 1 gram/kg. Therefore, a good therapeutic index of safety is present.
  • iodinin can be administered alone, that is, as a sole component of a filled capsule, it is preferred to formulate the compound in various dosage forms for oral or parenteral administration, such as tablets, syrups, sterile aqueous or non-aqueous suspensions and the like.
  • the oral dosage forms are prepared by the methods well known in the art, as are the parenteral and generally include a pharmaceutically acceptable carrier or diluent.
  • a method of lowering blood pressure in a hypertensive patient comprising administering a therapeutically effective amount of iodinin to said patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of reducing blood pressure in hypertensive patients by administering a therapeutically effective amount of iodinin to said patients.

Description

United States Patent [191 Jones et al.
IODININ AS AN ANTl-HYPERTENSIVE AGENT Inventors: Peter Hadley Jones, Lake Forest;
Pitambar Somani, Village of Libertyville, both of III.
Abbott Laboratories, North Chicago, Ill.
Filed: Mar. 20, 1972 Appl. No.: 236,179
Assignee:
US. Cl. 424/250 Int. Cl. A6lk 27/00 Field of Search 424/250 Primary Examiner-Jerome D. Goldberg AttorneyRobert L. Niblack 57 I ABSTRACT A method of reducing blood pressure in hypertensive patients by administering a therapeutically effective amount of iodinin to said patients.
-1 Claim, No Drawings IODININ AS AN ANTI-HYPERTENSIVE AGENT DETAILED DESCRIPTION OF THE INVENTION This invention relates to a method of reducing blood pressure in hypertensive patients using iodinin as the anti-hypertensive agent.
lodinin is represented by the formula The compound can be prepared according to the method described by U.S. Pat. No. 3,432,505.
lodinin has previously been reported to be an antibacterial agent (see U.S. Pat. No. 3,432,505). We have unexpectedly found that iodinin is an effective antihypertensive agent.
The anti-hypertensive activity of iodinin was first established in the spontaneously hypertensive rat procedure, Tabei et al. Clin. Pharmac. and Therap., ll (2): 269-274, (1970).
lodinin is effective as an anti-hypertensive agent at dosages of from approximately 0.1 to approximately 300 mg./kg. of body weight daily and is administered to hypertensive patients at such dosages, preferably by the oral route in divided dosages i.e., 3 to 4 times daily. It may also be co-administered with, for example, diuretics or tranquilizers.
The oral LD of iodinin is greater than 1 gram/kg. Therefore, a good therapeutic index of safety is present.
While iodinin can be administered alone, that is, as a sole component of a filled capsule, it is preferred to formulate the compound in various dosage forms for oral or parenteral administration, such as tablets, syrups, sterile aqueous or non-aqueous suspensions and the like. The oral dosage forms are prepared by the methods well known in the art, as are the parenteral and generally include a pharmaceutically acceptable carrier or diluent.
We claim:
1. A method of lowering blood pressure in a hypertensive patient comprising administering a therapeutically effective amount of iodinin to said patient.
US00236179A 1972-03-20 1972-03-20 Iodinin as an anti-hypertensive agent Expired - Lifetime US3764679A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23617972A 1972-03-20 1972-03-20

Publications (1)

Publication Number Publication Date
US3764679A true US3764679A (en) 1973-10-09

Family

ID=22888453

Family Applications (1)

Application Number Title Priority Date Filing Date
US00236179A Expired - Lifetime US3764679A (en) 1972-03-20 1972-03-20 Iodinin as an anti-hypertensive agent

Country Status (1)

Country Link
US (1) US3764679A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042894A1 (en) * 2007-07-13 2009-02-12 Food Industry Research And Development Institute Novel species of acrocarpospora, a method of preparing iodinin, and the uses of iodinin
WO2015063516A2 (en) 2013-11-01 2015-05-07 Universitetet I Oslo Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts 71: 79596 W (1969). *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042894A1 (en) * 2007-07-13 2009-02-12 Food Industry Research And Development Institute Novel species of acrocarpospora, a method of preparing iodinin, and the uses of iodinin
WO2015063516A2 (en) 2013-11-01 2015-05-07 Universitetet I Oslo Compounds

Similar Documents

Publication Publication Date Title
US6191153B1 (en) Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity
AU601237B2 (en) The use of paroxetine to treat pain
US4794103A (en) Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
RU95101385A (en) Products containing g-csf and tnf-binding protein
US3624216A (en) 8-substituted theophyllines as anti-inflammatory agents
US3885035A (en) Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
DK167559B1 (en) BUPRENORPHIC CONTAINED PHARMACEUTICAL SUPPLY
US3764679A (en) Iodinin as an anti-hypertensive agent
KR100420673B1 (en) Nasal administration to treat delayed nausea
Devière et al. Ischemic pancreatitis and hepatitis secondary to ergotamine poisoning
US3720768A (en) Aspergillic acid as an antihypertensive agent
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
AU630373B2 (en) Method of improving post-ischemic myocardial dysfunction using an ace inhibitor alone or in combination with a thrombolytic agent and combination
US4298611A (en) Process for reducing blood pressure in animals
US4122177A (en) Method of treating oligospermia and asthenospermia
US3895114A (en) Cyclic hydroxamic acids as antihypertensive agents
US3914425A (en) Antitussive codeine composition
KR900701301A (en) Treatment of myelosuppression associated with AIDS
US4663345A (en) Etodolac for treatment of gout
EP0256629A2 (en) Tolrestat or a salt thereof as an immuno-stimulating agent
US4195089A (en) Synergistic composition for malaria
US3806594A (en) Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium
JPS6116A (en) Improvement on organic compound
US3840663A (en) 5-alkylpipecolic acids as anti-hypertensive agents